Metabolic syndrome and risk of development of chronic kidney disease: The Niigata preventive medicine study

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 1, 2010, Pages 26-32

  Watanabe, Hiroshi ^a   Obata, Hiroaki ^a   Watanabe, Toru ^b   Sasaki, Shigeru ^b   Nagai, Kojiro ^c   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Niigata Association for Comprehensive Health Promotion and Research   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Kidney disease; Kidney dysfunction; Metabolic syndrome; Proteinuria

Indexed keywords

ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEINURIA;

AGED; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; METABOLIC SYNDROME X; MIDDLE AGED; PROTEINURIA; RISK FACTORS;

EID: 75449110732     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1058     Document Type: Article

References (36)

1. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005; 16: 3736-3741.
2. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72: 247-259.
3. The National Cholesterol Education Program (NCEP). Executive summary of the third report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
4. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
6. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92.
7. Landray MJ, Wheeler DC, Lip GY, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253.
8. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
9. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 2003; 52: 2346-2352.
10. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
11. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings fromthe National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-314.
12. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174.
13. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69: 369-374.
14. Kurella M, Lo JC, Chertow GM.Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140.
15. Ninomiya T, Kiyohara Y, Kubo M, et al Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 2006; 48: 383-391.
16. Luk AO, So WY, Ma RC, et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care 2008; 31: 2357-2361.
17. Ryu S, Chang Y, Woo HY, et al. Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am J Kidney Dis 2009; 53: 59-69.
18. Kitiyakara C, Yamwong S, Cheepudomwit S, et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int 2007; 71: 693-700.
19. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008; 117: 1255-1260.
20. Oda E, New criteria for 'obesity disease' in Japan. Circ J 2002; 66: 987-992.
21. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471-2477.
22. Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by theMDRD study equationmodified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
23. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
24. Fried L, Solomon C, Shlipak M, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 2004; 15: 3184-3191.
25. Meigs JB, Larson MG, Fox CS, Keaney JF Jr, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care 2007; 30: 2529-2535.
26. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-2135.
27. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403.
28. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 2008; 299: 2287-2293.
29. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-570.
30. Verma A, Ranganna KM, Reddy RS, Verma M,Gordon NF. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005; 96: 1290-1292.
31. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 2008; 26: 291-299.
32. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
33. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
34. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl JMed 2004; 351: 1296-1305.
35. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315.
36. Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167: 1130-1136.